EP 4294364 A2 20231227 - EMULSION COMPOSITION AND USES THEREOF IN THE PREVENTION AND/OR TREATMENT OF SKIN DAMAGE CAUSED BY RADIATION
Title (en)
EMULSION COMPOSITION AND USES THEREOF IN THE PREVENTION AND/OR TREATMENT OF SKIN DAMAGE CAUSED BY RADIATION
Title (de)
EMULSIONSZUSAMMENSETZUNG UND VERWENDUNGEN DAVON BEI DER VORBEUGUNG UND/ODER BEHANDLUNG VON DURCH STRAHLUNG VERURSACHTEN HAUTSCHÄDEN
Title (fr)
COMPOSITION EMULSION ET SES UTILISATIONS DANS LA PREVENTION ET/OU LE TRAITEMENT DES DOMMAGES CUTANES CAUSES PAR LES RAYONNEMENTS
Publication
Application
Priority
- FR 2101621 A 20210219
- EP 2022054044 W 20220218
Abstract (en)
[origin: CA3204646A1] The invention relates to a water-based composition in a form suitable for topical administration, comprising a vasoconstrictor. The invention is characterized in that it is in the form of an emulsion comprising liquid crystals and in that the composition comprises a vasoconstrictor chosen from brimonidine or salts thereof, in a solvent-based phase comprising: - polyethylene glycol in combination with propylene glycol; - a hydrophilic film-forming agent chosen from a polyvinylpyrrolidone/vinyl acetate copolymer, and polyvinylpyrrolidone in a non-crosslinked, crosslinked or acetate form, taken alone or in combination; - glycerin; - an emulsifier chosen from the combination PEG-75 stearate and glyceryl monostearate and the combination polyoxyethylene-20 sorbitan monostearate (polysorbate-60) and cetostearyl alcohol; - an oleic acid or an oleyl alcohol, preferentially an oleyl alcohol; - and an oily phase suitable for obtaining an emulsion comprising liquid crystals.
IPC 8 full level
A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/107 (2006.01); A61K 31/498 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/14 (2017.01); A61K 47/32 (2006.01); A61P 17/00 (2006.01)
CPC (source: EP KR US)
A61K 9/0014 (2013.01 - EP KR); A61K 9/06 (2013.01 - EP KR); A61K 9/107 (2013.01 - EP US); A61K 9/1274 (2013.01 - US); A61K 31/498 (2013.01 - EP KR US); A61K 47/10 (2013.01 - EP KR); A61K 47/12 (2013.01 - EP KR); A61K 47/14 (2013.01 - EP KR); A61K 47/22 (2013.01 - US); A61K 47/32 (2013.01 - EP KR); A61K 47/36 (2013.01 - KR US); A61P 17/00 (2018.01 - EP KR); A61P 17/02 (2018.01 - US); A61P 17/04 (2018.01 - US); A61P 29/00 (2018.01 - KR)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
FR 3119986 A1 20220826; FR 3119986 B1 20240216; AU 2022222303 A1 20230921; CA 3204646 A1 20220825; CN 116887811 A 20231013; EP 4294364 A2 20231227; JP 2024507011 A 20240215; KR 20230147155 A 20231020; US 2024100045 A1 20240328; WO 2022175434 A2 20220825; WO 2022175434 A3 20221013; ZA 202306742 B 20240228
DOCDB simple family (application)
FR 2101621 A 20210219; AU 2022222303 A 20220218; CA 3204646 A 20220218; CN 202280015431 A 20220218; EP 2022054044 W 20220218; EP 22706816 A 20220218; JP 2023574755 A 20220218; KR 20237031786 A 20220218; US 202218264289 A 20220218; ZA 202306742 A 20230630